NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, announced today that Michael Higgins has joined the firm as Senior Research Analyst covering the Biotechnology and Specialty Pharmaceuticals sectors.
Prior to joining ROTH, Mr. Higgins covered the biopharmaceuticals sector for Rodman & Renshaw, where his coverage included generic drug companies as well as clinical-stage biotechnology companies. Throughout his career, Mr. Higgins has published many broad industry research reports (i.e. the advanced wound care market), is a frequent speaker at industry conferences and has been featured in numerous interviews with the media.
Mr. Higgins founded a proprietary research firm, 4Sight Research Partners, LLP, and was an integral member of two emerging research firms, Brinson Patrick Securities Corporation and Highline Research Advisors, LLC.
Mr. Higgins began his investment career at Dafna Capital in Los Angeles, where he focused on specialty pharmaceuticals and late stage biotechnology companies. This followed a decade at Procter & Gamble Pharmaceuticals, where he was a pharmaceutical sales representative, launching over a dozen products to primary care and specialty physicians. Mr. Higgins earned his Bachelor of Science in Finance from the University of Wisconsin-Stevens Point and his MBA from Marquette University.
Higgins commented, “I am delighted to join ROTH, a highly regarded investment bank with a strong track record in healthcare. I am very impressed by the quality and depth of the ROTH research universe. My goal is to provide a significant contribution by identifying and analyzing emerging specialty pharmaceutical and biotechnology companies that are translating science and clinical findings to actionable investment recommendations.”
“We are pleased to add Michael to our award-winning healthcare research team. His experience within the biopharmaceuticals sector and his respected reputation among companies and investors will be valuable assets to our platform,” said Jeff Martin, CFA, ROTH’s Director of Research.
Byron Roth, CEO of ROTH Capital commented, “Michael is a recognized senior research analyst and brings to ROTH a wealth of industry expertise and relationships that will add important resources to our platform. We are excited to welcome him as a part of the ROTH healthcare team.”
Since the beginning of 2010, ROTH has assisted its Healthcare clients in raising approximately $9.6 billion in over 255 healthcare transactions. ROTH’s Healthcare clients cover a broad spectrum of sectors including biotechnology, pharmaceuticals, medical technologies and devices, and healthcare services. (ROTH as of 04/24/2015)
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
